IP Library Granted Patent US 8,586,602
Granted Patent B2
US 8,586,602 · App. 13/486,414 · Granted Nov 19, 2013

Derivatives of 7 alkynyl-1,8 naphthyridones, preparation method thereof and use of same in therapeutics

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,586,602
App. No.
13/486,414
Granted
Nov 19, 2013
Kind
B2
Abstract

The disclosure relates to method of treating a disease in which VEGFR-3 is involved, comprising administering a therapeutically effective amount of a compound of the formula wherein R 1 , R 2 , R 3 , and R 4 are as defined in the disclosure, to compositions containing them, to processes for preparing them, and to their use in therapeutics.

Claims (26)

1. A method treating a disease selected from the group consisting of restenosis, nephrosclerosis, and liver cirrhosis, comprising administering to a patient in need thereof an effective dose of a compound of formula (I):

wherein:

R 1 and R 2 represent, independently of one another:

a hydrogen atom, or

a C 1 -C 7 alkyl group optionally substituted by one or more alkoxy groups;

R 3 represents a C 1 -C 7 alkyl group;

R 4 represents a hydrogen atom or a C 1 -C 4 alkyl group;

Y represents a C 1 -C 4 alkoxy group or an —NRR′ or —O(CH 2 ) n —C(O)—NRR′ group where R and R′ are as defined below and n is an integer equal to 1 or 2;

R″ represents a C 1 -C 4 alkyl group; and

R and R′ represent, independently of one another, a hydrogen atom, a —CO—(C 1 -C 4 alkyl) group or a —COOR″ group, where R″ is as defined above;

or an acid addition salt thereof, or an enantiomer or diastereoisomer thereof, or a mixture thereof.

2. The method according to claim 1 wherein the disease is restinosis.

3. The method according to claim 1 or 2 , wherein Y represents a C 1 -C 4 -alkoxy group;

or an acid addition salt thereof, or an enantiomer or diastereoisomer thereof, or a mixture thereof.

4. The method according to claim 1 or 2 , wherein Y represents an —NRR′ group,

or an acid addition salt thereof, or an enantiomer or diastereoisomer thereof, or a mixture thereof.

5. The method according to claim 1 or 2 , wherein Y represents an —O(CH 2 ) n —C(O)—NRR′ group n is an integer equal to 1 or 2;

or an acid addition salt thereof, or an enantiomer or diastereoisomer thereof, or a mixture thereof.

6. The method according to claim 1 or 2 , where the compound is selected from the group consisting of:

(±)-2-amino-7-(3,4-dimethoxy-3-methylbut-1-yn-1-yl)-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide;

2-amino-7-[3-(2-amino-2-oxoethoxy)-3-methylbut-1-yn-1-yl]-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide; and

2-amino-1-ethyl-7-(3-methoxyprop-1-yn-1-yl)-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide;

or an acid addition salt thereof.

7. The method according to claim 1 or 2 wherein R 1 and R 2 are hydrogen, R 3 is ethyl, R 4 is methyl and Y is

or an acid addition salt thereof.

8. The method according to claim 1 or 2 where R 1 , R 2 and R 4 is methyl, R 3 is ethyl and Y is NH 2 or an acid addition salt thereof.

Assignments (1)
CHANGE OF ADDRESS Recorded Jul 3, 2024
From: SANOFI
To: SANOFI
Reel/Frame 068105/0767 →